Impilo closes a EUR 320 million Continuation Fund

Mannheimer Swartling has acted as legal counsel for Impilo in connection with the establishment of the continuation fund Impilo Orphan Drugs.

The capital was raised from an international investor base and will be invested in Immedica. This will enable Impilo and Immedica to continue their partnership in cooperation with KKR, which recently became an equal owner of Immedica alongside Impilo.

Impilo is a Nordic investment company focused on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health related industries. Impilo has a well-diversified portfolio of healthcare investments and manages approximately EUR 1 billion of capital from leading Nordic and international investors.